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Influence of folic acid on the CNS is still unclear. Folate has a neuroprotective effect, while on the other hand excess 
folate can exacerbate seizures in epileptics. The aim of the present study was to examine the effect of subchronic 
administration of folic acid on behavioural and electroencephalographic (EEG) characteristics of DL homocysteine 
thiolactone induced seizures in adult rats. The activity of Na+/K+-ATPase and Mg2+-ATPase in different brain 
regions was investigated. Adult male Wistar rats were divided into groups: 1. Controls (C, 0.9% NaCl); 2. DL 
homocysteine-thiolactone 8.0 mmol/kg (H); 3. Subchronic supplementation with folic acid 5 mg/kg for 7 days (F) 
and 4. Subchronic supplementation with F + single dose of H (FH). Seizure behaviour was assessed by incidence, 
latency, number and intensity of seizure episodes. Seizure severity was described by a descriptive scale with grades 
0–4. For EEG recordings, three gold-plated recording electrodes were implanted into the skull. Subchronic 
supplementation with folic acid did not affect seizure incidence, median number of seizure episodes and severity in 
FH, comparison with H (p > 0.05). The majority of seizure episodes in all groups were of grade 2. There were no 
significant differences in lethal outcomes at 24 h upon H injection in the FH vs. H group. The activity of Na+/K+- 
ATPase and Mg2+-ATPase was significantly increased in almost all examined structures in the FH vs. H group. 
Subchronic folic acid administration did not exacerbate H induced seizures and completely recovered the activity of 
ATPases.
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Folic acid, also referred to as folate, is one of the 13 essential vitamins obtained from dietary 
sources or supplements. Among water soluble group B vitamins, folates have attracted much 
scientific and public health interest in recent years (7). Folate consists of the pteridine ring to 
which p-aminobenzoic acid is attached and one or more glutamate residues, the latter being 
the major excitatory neurotransmitter in the brain (28). 
Folates are required both in the remethylation of homocysteine to methionine and in the 
synthesis of S-adenosyl-methionine (SAM), the principal biological methyl donor in 
numerous methylation reactions (14, 45). Methylation of DNA, RNA and proteins by SAM 
is an important epigenetic determinant in gene expression, DNA stability, DNA integrity and 
mutagenesis. Folate also plays an essential role in the de novo synthesis of purines and 
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thymidylate, which is required in DNA replication and repair (20). Folate, via its donation of 
a methyl group, plays a key role in neurotransmitter synthesis and myelin synthesis and 
repair (12).
Decades of research suggest that maternal folate deprivation might be a cause of neural 
tube defect (35, 49) and childhood brain tumors (10). Folate deficiency has been associated 
with reduced hippocampal and amygdalar volumes and global brain atrophy in humans 
(8, 41). 
An adequate amount of folate is required to maintain low levels of homocysteine in the 
central nervous system (CNS), which may exert direct neurotoxic and pro-oxidative actions 
(15, 22). A growing number of epidemiological studies have linked folate deficiency and 
resultant elevated plasma total homocysteine levels with an increased risk of vascular disease, 
cerebral ischemia, seizures and neurodegenerative and neuropsychiatric diseases, including 
Alzheimer`s and Parkinson`s disease (29, 31). Some reports have shown that folic acid 
administration can reduce blood homocysteine concentrations in humans and rats (23, 38) 
and reduce the risk for these diseases (44).
Homocysteine is a sulphur-containing amino acid recently recognized as one of the 
most potent excitatory agents of the central nervous system (9, 34) and the major risk factor 
for numerous brain disorders like cognitive decline and dementia, Alzheimer’s, Parkinson’s 
and Huntington’s disease (19, 39) and epilepsy (13). Stanojlović et al. (42) have recently 
showed that acute administration of homocysteine to adult rats significantly alters neuronal 
circuits, leading to epileptogenic activity and convulsive episodes in adult rats.
Na+/K+-ATPase is a key enzyme involved in the maintenance of brain excitability and 
some authors reported elevated Na+/K+-ATPase activity in certain animal models of epilepsy 
(3). On the other hand, reduced activity of this enzyme was found in cerebral ischemia (47), 
epilepsy (11) and neurodegeneration (24) and it possibly correlates with excitotoxic 
mechanisms. 
In view of these considerations, the aim of the present study was to examine the effect 
of subchronic supplementation with folic acid on DL homocysteine thiolactone induced 
seizures and on brain Na+/K+-ATPase and Mg2+-ATPase activity. 
Materials and Methods
Animals and experimental conditions 
All experimental procedures were carried out in accordance with The European Council 
Directive (86/609/EEC), and were approved by the Animal Care Committee of the University 
of Belgrade (298/5-2).
Adult male Wistar rats (170–200 g), obtained from the Military Medical Academy 
Breeding Laboratories, Belgrade (Serbia) were used. The animals were housed individually 
in transparent plastic wire-covered cages (55×35×15 cm) with free access to food and water, 
under controlled ambient conditions (22–23 oC, 50–60% relative humidity, 12/12 h light/dark 
cycle with light switched on at 8 a.m.). All tests took place during light period, between 8:00 
and 16:00 h. The acclimatization period lasted for 7 days. 
Study design and experimental procedures 
The animals were divided into the following groups: 1. Controls, saline-injected (C, 0.9% 
NaCl, n = 10); 2. DL homocysteine-thiolactone 8.0 mmol/kg (H, n = 9); 3. Subchronic 
supplementation with folic acid 5 mg/kg for 7 days (F, n = 8) and 4. Subchronic 
supplementation with folic acid for 7 days (FA) + single dose of HT (FH, n = 9). 
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Each rat was used only once. All the substances were freshly dissolved in saline and 
after adjusting the pH to 7.4, administered intraperitoneally (i.p.) in a volume of 0.1 ml/100 
g rat body weight. 
Behavioural recordings
Behavioural manifestations of homocysteine induced epilepsy in rats were recorded. The 
animals placed in separate transparent plastic cages (55 × 35 × 15 cm) were observed for 120 
min for the occurrence of convulsive behaviour. This was assessed by the incidence of 
seizures (the number of convulsing animals out of the total number of rats), the number of 
seizure episodes per rat and the seizure severity. Seizure severity was determined by a 
modified descriptive rating scale reported by Stanojlović et al. (42) with grades defined as: 
grade 1 – head nodding, lower jaw twitching; grade 2 – myoclonic body jerks (hot plate 
reaction), bilateral forelimb clonus with full rearing (Kangaroo position); grade 3 – 
progression to generalized clonic convulsions followed by tonic extension of fore and hind 
limbs and tail and grade 4 – prolonged severe tonic-clonic convulsions lasting over 10 sec 
(status epilepticus) or frequent repeated episodes of clonic convulsions for an extended 
period of time (over 5 min). In addition, latency to seizure, defined as a time from H injection 
to the first seizure episode, was also recorded. For rats without seizures, 90 min latency time 
was scored. Lethality was recorded 90 min and 24 h after homocysteine administration.
Surgery and EEG recordings
The rats were anesthetized with pentobarbital sodium (50 mg/kg, i.p.), placed in a stereotaxic 
apparatus and three gold-plated recording electrodes were implanted over frontal, parietal 
and occipital cortices (for details see ref 42). Animals were allowed at least 7 days recovery 
from the surgery and then acclimated to the recording environment for at least 24 h. During 
that period, animals were supervised for the occurrence of convulsive behaviour. 
An 8-channel EEG apparatus (RIZ, Zagreb, Croatia) was used. The signals were 
digitized using a SCB-68 data acquisition card (National Instruments Co, Austin, Texas, 
USA). A sampling frequency of 512 Hz/channel and 16-bit A/D conversion were used for the 
EEG signals. The cut-off frequencies for EEG recordings were set at 0.3 Hz and 80 Hz for 
the high-pass and low-pass filters, respectively. Ambient noise was eliminated using a 50 Hz 
notch filter. Data acquisition and signal processing were performed with LabVIEW software 
developed in the laboratory (NeuroSciLaBG). 
All EEG recordings in freely moving rats were visually monitored and screened for 
seizure activity and stored on disk for subsequent off-line analysis. The power spectral 
density (PSD) of the characteristic 12 s epochs was calculated. The fast Fourier transform 
method (linear detrending, Hanning window, 0.083 Hz resolution) was applied to obtain 
estimates of total PSD (μV2/Hz). Epochs with artifacts and with a significant amount of 
contamination by electromyographic activity were carefully detected and excluded from the 
analysis. The rats were removed from the recording chambers and returned to its home cages 
upon completion of the 120 min recording sessions.
Biochemical analyses 
In a separate series of experiments, the activity of Na+/K+-ATPase and Mg2+-ATPase in the 
cortex, the hippocampus and the brain stem in the following groups C, H, F and FH (n = 16 
per group) were analyzed.
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Synaptic plasma membrane preparation
Animals were killed without anesthesia by decapitation and the brains rapidly excised. The 
cortex, hippocampus and brain stem were dissected out and pooled (6/pool) for immediate 
preparation of synaptic plasma membranes (SPM). The SPM from the cortex, the hippocampus 
and the brain stem were isolated as described by Cohen et al. (6) and modified by Towle and 
Sze (46). Mitochondrial contamination and protein content were determined according to the 
standard procedure (16).
ATPase assays
SPM ATPase activities were assayed in a standard medium consisting of 50 mM Tris–HCl, 
pH 7.4, 100 mM NaCl, 20 mM KCl and 5.0 mM MgCl2 and 25 µg of SPM proteins were 
added. Incubation mixtures were preincubated for 10 min at 37 oC. The reaction was initiated 
by the addition of 2.0 mM ATP to a final volume of 200 µl. The reaction was terminated after 
10 min by adding 22 µl ice-cold 3.0 M HClO4 and immediately cooled with ice. The inorganic 
orthophosphate (Pi) released by ATP hydrolysis was measured using a modified 
spectrophotometric procedure (48) by reading the absorbance at 690 nm. The activity 
obtained in the absence of NaCl and KCl was attributed to Mg2+-ATPase. Na+/K+-ATPase 
activity was calculated as the difference between the total ATPase (obtained in the presence 
of Na+, K+ and Mg2+ ions) and Mg2+-ATPase activity. 
SPM ATPase activities were determined in pooled brain tissues (cortex, hippocampus 
and brain stem). The results are expressed as mean of specific enzyme activity ± SD from at 
least four independent experiments done in triplicates. Specific enzymatic activities are 
expressed as µM of inorganic phosphate released per mg protein per hour.
Drugs 
All drugs were of analytical purity and purchased from Sigma-Aldrich Chemical Co., USA.
Data analyses, statistical analyses
Significance of the differences in the incidence of seizures and lethality was evaluated by 
Fisher’s exact probability test. Since the normal distribution of the data on seizure latency, 
number and intensity of seizure episodes have not been estimated by Kolmogorov–Smirnov 
test, the non-parametric analyses (Kruskal–Wallis ANOVA and Mann–Whitney U-test) were 
used to determine the statistical significance of the differences between the groups (*p < 0.05, 
**p < 0.01). The results were expressed as medians with 25th and 75th percentiles. 
The significance of the differences in the activity of Na+/K+-ATPase and Mg2+-ATPase 
between the groups was estimated by Student’s t-test. The results are expressed as the means 
± SD.
Results
Seizure behaviour
Animals in the C and F groups, expressed normal gross behavioural activity without any 
signs of seizures and no lethality was recorded. Convulsions were observed in all rats that 
received DL homocysteine-thiolactone at a dose of 8 mmol/kg. Subchronic supplementation 
with folic acid did not affect seizure incidence in the FH (77.7%, p > 0.05) in comparison 
with the H (100.00%) group (Fig. 1). 
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Fig. 1. The effect of subchronic supplementation with folic acid on seizure incidence in experimental groups. 
Wistar rats were i.p. treated with DL homocysteine-thiolactone 8 mmol/kg (H) or with folic acid  
(5 mg/kg for 7 days) prior to H injection (FH). The significance of the differences between the groups was 
estimated by Fisher’s exact probability test
Folic acid supplementation decreased the median latency to the first seizure episode in 
the FH [20.0 (17.7–90.0) min] (p > 0.05) compared to the H group [28.0 (21.0–39.0) min] but 
not significantly (Fig. 2A). Median number of seizure episodes per rat in FH [2.00 (0.00–
6.00)] (p > 0.05) were not affected by subchronic supplementation with folic acid, compared 
to the H [4.00 (1.00–5.00)] group (Fig. 2B). Median seizure episode severity was not affected 
by folic acid supplementation [2.00 (1.00–4.00)] compared to the group H [2.00 (1.00–4.00)] 
(Fig. 2C). 
In order to examine the seizure severity, the statistical significance of seizure episode 
severity distribution was estimated by Fisher’s exact probability test. The majority of seizure 
episodes in all groups: H (36.0%) and FH (50.0%) were of grade 2 (Table I). Folic acid 
supplementation increased lethal outcomes 90 min after H injection in the FH group (77.7%) 
but statistical significance was not attained when compared to the H (44.4%). There were no 
significant differences in lethal outcomes 24 h upon H injection in FH comparing to the H 
group (Table II). 
EEG analysis
Bioelectrical activity recorded from the frontal, parietal and occipital cortex in the group of 
rats treated only with folic acid was similar to the one in the control group, revealing no 
epileptiform graph elements, while PSD was dominant in the alpha frequency range. 
The first signs of bioelectrical activity of the group treated with H were isolated spikes, 
which progressed to the spike wave complexes and burst of spikes. After 45 min of DL 
homocysteine-thiolactone administration and during grade 2 in the FH group, we recorded 
generalized high-voltage synchronous bursts of polyspikes in EEG that have been higher 
amplitude and PSD compared to the H group (Fig. 3). Dissociation between EEG pattern and 
motor phenomena, as well as low electroclinical correlation was common to all experimental 
recordings.
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Fig. 2. The effect of subchronic supplementation with folic acid on median latency to the first seizure episode (A), 
a number of seizure episodes per rat (B) and seizure severity (C).
The significance of the differences between the groups was estimated by Kruskal–Wallis ANOVA and Mann–
Whitney U-test. For the details see caption to Fig. 1
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Table I. The effect of subchronic folic acid supplementation on seizure severity grade distribution  
in experimental groups
Grade (%) Experimental groups Significance
H FH
1 16.0 6.25 p > 0.05
2 36.0 50.0 p > 0.05
3 28.0 37.5 p > 0.05
4 20.0 6.25 p > 0.05
Severity of seizure episode was assessed by descriptive rating scale with defined grades 1–4.  
Statistical significance of the differences was estimated by Fisher’s exact probability test. 
For the details see caption to Fig. 1 
Table II. The effect of subchronic folic acid supplementation on lethality recorded  
90 min and 24 h after DL-homocysteine thiolactone administration
Lethality (%) Experimental groups Significance
H FH
After 90 min 44.4 77.7 p > 0.05
After 24 h 88.8 77.7 p > 0.05
Lethality – number of exited rats out of total number of rats in group expressed  
in percentage. Significance of the differences between the groups was estimated  
by Fisher’s exact probability test. For the details see caption to Fig. 1 
Fig. 3. Representative EEG tracings (the left panels) and corresponding power spectra density  
(the right panels) in experimental groups, recorded during grade 2 convulsions,  
45 min after DL homocysteine-thiolactone administration. For the details see caption to Fig. 1
158
Acta Physiologica Hungarica 102, 2015
Rasic-Markovic A et al.
Brain Na+/K+-ATPase and Mg2+-ATPase activities
Administration of DL homocysteine-thiolactone produced a significant reduction of Na+/K+-
ATPase activity in all examined brain structures (the cortex, the hippocampus and the brain 
stem by –64.94%, p < 0.01, –83.89%, p < 0.01 and –85.44%, p < 0.01, respectively) comparing 
to the control. Subchronic supplementation with folic acid, when administered alone, 
significantly increased the activity of this enzyme in the cortex (+138.00%, p < 0.01), the 
hippocampus (+78.22%, p < 0.05) and the brain stem (+70.91%, p < 0.05), compared to 
controls. When H was administered following subchronic supplementation with folic acid 
Na+/K+-ATPase activity significantly increased in the cortex (+180.38%; p < 001) and the 
brain stem (+89.09%, p < 0.05) comparing to the C; while in the hippocampus, the activity 
of this enzyme returned to the baseline values (Fig. 4A). 
In animals treated with DL homocysteine-thiolactone the activity of Mg2+-ATPase was 
significantly elevated in the cortex (+44.52%, p < 0.05), while no significant changes in the 
activity of this enzyme were observed either in the hippocampus (–5.56%, p > 0.05) or in the 
brain stem (+2.63%, p > 0.05). Folic acid supplementation significantly increased the activity 
of Mg2+-ATPase in the cortex (+261.27%, p < 0.01), the hippocampus (+108.33%, p < 0.01), 
and the brain stem (+68.42%, p > 0.05), comparing to the C. In the FH group Mg2+-ATPase 
activity significantly increased in all examined structures: the cortex (+311.31%, p < 0.01), 
the hippocampus (+108.33%, p < 0.01) and the brain stem (+147.38%, p < 001), comparing 
to the C (Fig. 4B).
Fig. 4A. The effect of DL 
homocysteine-thiolactone (H), 
supplementation with folic acid  
(5 mg/kg for 7 days) (F) and 
supplementation with folic acid prior 
to H administration (FH)  
on Na+/K+-ATPase activity  
in different parts of brain  
*p < 0.05, ** p < 0.01 vs. C
Cortex (Cx), hippocampus (Hp),  
brain stem (Bs)
Fig. 4B. The effect of DL 
homocysteine-thiolactone (H), 
supplementation with folic acid  
(5 mg/kg for 7 days) (F)  
and supplementation with folic  
acid prior to H administration (FH) 
on Mg2+-ATPase activity  
in different parts of brain  
** p < 0.01 vs. C
Cortex (Cx), hippocampus (Hp),  
brain stem (Bs)
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Discussion
The link between epilepsy and folic acid is complex. Patients on antiepileptic drugs are prone 
to low folate and vitamin B12 and consequent hyperhomocysteinemia, which can promote 
excitotoxicity and lead to increased neuronal injury and cell death (1). On the other hand, 
folic acid has been accused of being a potential risk, for provoking seizures and poor seizure 
control (37).
In the present study, we investigated the effect of subchronic supplementation with folic 
acid on DL homocysteine-thiolactone induced seizures and Na+/K+-ATPase and Mg2+-ATPase 
activity in different CNS regions. 
Folic acid plays an important role in neuronal development, neuroplasticity and in the 
maintenance of neuronal integrity. Studies have shown that hyperhomocysteinemia actually 
represents a measure of functional folate deficiency (18). Low folate status and elevated 
homocysteine are responsible for cerebrovascular, neurodegenerative and psychiatric 
disorders (21, 30). This detrimental effect can be attributed to increased generation of ROS, 
excitotoxicity and mitochondrial dysfunction which leads to apoptosis. Previous results from 
our laboratory have shown that folic acid works as an anticonvulsive agent in H induced 
seizures, when it is given acutely in large doses (27). These results are consistent with 
previous results regarding the role of folic acid in preventing neuronal death and excitotoxicity 
and it appears that folic acid is a potent inhibitor of kainic, NMDA receptors, nitric oxide and 
cyclic guanosine monophosphate synthesis (4).
The results presented here demonstrate that subchronic supplementation with folic acid 
(5 mg/kg) did not exacerbate behavioural characteristics of H induced seizures; incidence, 
latency, number and intensity of seizure episodes were not significantly different compared 
to H. Spectral power densities of ictal episodes were higher in the FH group, but not in a 
significant manner to be claimed as proconvulsive. Still, remains the question, is this 
discrepancy in the results due to the dose or the time dependent manner of administration of 
folic acid. 
Studies have shown that excess folate has a direct neurotoxic effect and may function as 
endogenous excitatory amino acid (2). Recent findings of Budni et al. (5), suggested the role 
of folic acid in the modulation of neuronal excitability via inhibition of different types of K+ 
channels, which may explain why subchronic supplementation failed to produce an 
anticonvulsive effect on H induced seizures. Furthermore, we noticed that lethal outcomes in 
the FH group was higher 90 min after H injection and did not increase up to 24 h after H. 
Although statistical significance was not attained when compared to the H, the mechanism 
should be examined in further experiments.
There is evidence that the nervous system response is related both to the dose and the 
duration of treatment, as well as the folate status of the patient (32). After ingestion, folic acid 
is reduced by dihydrofolate reductase and then converted to biologically active forms. If 
intake exceeds the body`s ability to reduce folic acid, unmetabolized folic acid will be found 
in blood. There are concerns that exposure to unmetabolized folic acid may be associated 
with adverse effects (33) and high lethality outcomes 90 min after H injection.
Our previously published data, demonstrated a strong inhibitory effect of homocysteine 
thiolactone on the Na+/K+-ATPase activity in SPM of the rat hippocampus, the brain stem and 
the parietal cortex of rats without affecting the Mg2+-ATPase activity (36, 43). The results 
presented here demonstrate that subchronic supplementation with folic acid completely 
reversed the inhibitory effect of homocysteine thiolactone and even increased Na+/K+-ATPase 
activities in the cortex and the brain stem, compared to the baseline values. Inhibition of 
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Na+/K+-ATPase by homocysteine may result from the oxidation of thiol groups, mediated by 
free radicals (25). On the other hand, folic acid and its active metabolites elicit direct 
antioxidative effects: it reduces superoxide anion production via NADPH oxidase, attenuates 
the xanthine oxidase activity, and restores SOD activity in hyperhomocysteinemic rats 
(17, 40).
Dietary therapies represent a potentially valuable adjunct to other conventional epilepsy 
treatments. On the other hand, dietary supplementation and fortification of cereal grain 
products with folic acid, imposes a need to examine the potential beneficial or adverse effects 
in patients with different medical conditions.
It is clear that the relationships between folate and health outcomes are complex; we 
need further investigation for a better understanding of the relevant biological mechanisms to 
avoid misinterpretation.
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